Discovery falls on Surfaxin approvable letter

Discovery Labs (NASDAQ:DSCO) fell $1.45 (50%) to $1.45 on 21.4 million shares on Friday after the company received a third approvable letter from FDA for Surfaxin lucinactant to prevent respiratory di...